Remote ischemic preconditioning to reduce contrast-induced nephropathy.

Remote ischemic preconditioning to reduce contrast-induced nephropathy. - RIPCIN study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37244

Enrollment

Registered

2012-10-16

Start date

2012-10-17

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced kidney injury contrast-induced nephropathy

Interventions

After informed consent, the researcher checks the scheduled time of the diagnostic and/or therapeutic procedure with iodine-containing contrast at the department of (interventional) radiology. The r

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusioncriteria: •Interventions with expected intravascular contrast volume > 100 mL: -Thoracic Endovascular Aortic Repair (TEVAR) -Endovascular Aortic Repair (EVAR) -Digital Substraction Angiography (DSA) -Percutaneous Transluminal Angioplasty (PTA) -Percutaneous Intentional Endovascular Revascularisation (PIER) -Carotic Artery Stenting (CAS) -Percutaneous coiling/embolisation procedures -Computed Tomographic Angiography •High-risk of CIN (according CBO guideline): - eGFR 75 years, anaemia (Ht

Exclusion criteria

Exclusion criteria: -Age

Design outcomes

Primary

Measure	Time frame
Change in serum creatinine levels from baseline (day prior to contrast administration) to 48 hours after contrast administration.	—

Secondary

Measure	Time frame
-change in biomarkers (for kidney injury) levels in blood and urine from baseline to 24 and/or 48 hours after contrast administration. -incidence of CIN (>25% rise in serum creatinine) -death, rehospitalization and/or hemodialysis within 6 weeks after contrast-administration	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)